当缩减标签足够精简时,美国联邦巡回法院仍然重启了对仿制药企业的诱导侵权诉讼

近日,在Amarin Pharma诉Hikma Pharmaceuticals USA 案(编号2023-1169)中,美国联邦巡回法院推翻了特拉华州地区法院的裁决,认为Amarin的诉状合理地声称Hikma积极诱导了医疗服务提供者的直接侵权,不过同时还表示 “可能同意地区法院(和Hikma)”认为Hikma的缩减标签本身在法律上并没有推荐、鼓励或推动任何侵权使用。

Continue reading “当缩减标签足够精简时,美国联邦巡回法院仍然重启了对仿制药企业的诱导侵权诉讼”

© 2009- Duane Morris LLP. Duane Morris is a registered service mark of Duane Morris LLP.

The opinions expressed on this blog are those of the author and are not to be construed as legal advice.

Proudly powered by WordPress